Global Alliance For Tb Drug Development Inc
88% goes to programs $3 to raise $100 Strong reserves
Global Alliance For Tb Drug Development Inc is a 501(c)(3) organization based in New York, New York, registered in 2000, with $63,732,557 in FY2024 revenue. CharityIndex grades it A, and it directs about 88% of spending to programs.
80 Pine Street 20th Flr, New York, NY, 10005 EIN 13-4128413 Since 2000
Revenue (FY2024)
$63.7M
▲ 5.8% vs prior year
Medical Research median: $217K
Expenses (FY2024)
$61.5M
Net assets
$176.3M
Employees
50
CharityIndex rating
One independent A+ to F grade from four published criteria, each scored separately from IRS filings and combined by weight.
A
AProgram efficiency40% of the rating88% to programs · $3 to raise $100
Measures how much of every dollar spent actually reaches programs, plus what it costs to raise $100 of donations. The worse of the two measures sets the letter (85%+ to programs is an A; under $15 to raise $100 is an A), averaged over the three most recent filings. For Global Alliance For Tb Drug Development Inc: 88% to programs · $3 to raise $100 earns a A on this criterion. See the exact thresholds →
AFinancial health25% of the rating34 mo reserves · +3% margin
Measures whether the organization is built to last: how many months its reserves would cover expenses (3+ months earns an A-range score, but hoarding 5+ years of budget is capped) and whether it runs a surplus or a deficit. For Global Alliance For Tb Drug Development Inc: 34 mo reserves · +3% margin earns a A on this criterion. See the exact thresholds →
A+Governance25% of the rating6 of 6 checks met
Checks how the organization is run, from its own Form 990: an independent board majority, a board of five or more, conflict-of-interest, whistleblower and document-retention policies, and independently audited financials. The share of disclosed checks that pass sets the letter. For Global Alliance For Tb Drug Development Inc: 6 of 6 checks met earns a A+ on this criterion. See the exact thresholds →
A+Transparency10% of the rating5 of 5 disclosure signals
Counts five disclosure signals: a recent filing, a mission statement, program descriptions, a listed website, and the full expense breakdown. More disclosure, better letter. For Global Alliance For Tb Drug Development Inc: 5 of 5 disclosure signals earns a A+ on this criterion. See the exact thresholds →
Show this grade on your website
A live seal — it updates automatically when the grade changes and links donors to this verified profile.
Mission
To accelerate the discovery & development of new drugs to facilitate the control of tuberculosis throughout the world and the accessibility of these drugs to the global community.
What they do
Public affairs and policy - tb alliance maintains critical alliances with public and private organizations to raise awareness about tuberculosis ("tb") and advocate for public and private involvement in research for the public good. specifically, tb alliance negotiates terms that support the development and access of new affordable anti-tb drugs equitably for those areas most in need while encouraging the private sector on the development of these medicines. tb alliance continues to pursue an explicit commitment to our "aaa mandate" - that all new products will be adopted, available and affordable to those with tb.
Business development - tb alliance negotiates, implements and manages agreements with public and private organizations worldwide and does so by adhering to sound business practices while ensuring the public good. specifically, tb alliance negotiates terms that support the development and access of new affordable anti-tb drugs equitably to those areas most in need while encouraging the private sector to help develop new medicines for tb indications.
Contact & location
- Address
- 80 Pine Street 20th Flr, New York, NY, 10005
- City
- New York
- State
- New York
- Category
- Medical Research
- Subcategory
- Organ Research
- Phone
- …
- Website
- …
Financial trends
Revenue grew from $58.0M (FY2017) to $63.7M (FY2024) across 8 reported years.
Financial snapshot
Financial health & position (FY2024)
Liabilities $28.0MNet assets $176.3M
Operating margin
3.5%
Revenue exceeded expenses in the latest fiscal year.
Total assets
$204.3M
Total liabilities
$28.0M
Net assets
$176.3M
Salaries & benefits
$18.0M
29% of expenses
Board members
12
11 independent
Financials by year
| Fiscal year | Revenue | Expenses | Net assets | Total assets | Form |
|---|---|---|---|---|---|
| 2024 | $63,732,557▲5.8% | $61,508,783▲11.1% | $176,309,829▲2.7% | $204,316,428▲3.5% | 990 |
| 2023 | $60,240,486▲7.2% | $55,378,579▼0.7% | $171,699,550▲3.9% | $197,319,541▲11.7% | 990 |
| 2022 | $56,212,963▼4.2% | $55,785,890▼2.9% | $165,180,519▼0.3% | $176,686,879▼5.8% | 990 |
| 2021 | $58,653,379▼4.3% | $57,430,605▼7.0% | $165,640,573▲0.7% | $187,560,796▼1.9% | 990 |
| 2020 | $61,267,452▼65.0% | $61,720,389▼11.2% | $164,457,926▼0.1% | $191,155,661▲0.9% | 990 |
| 2019 | $174,873,899▲176% | $69,535,079▲15.3% | $164,687,790▲177% | $189,418,881▲152% | 990 |
| 2018 | $63,283,490▲9.1% | $60,315,645▲7.5% | $59,409,768▲5.0% | $75,171,538▲3.0% | 990 |
| 2017 | $58,006,498 | $56,120,604 | $56,554,339 | $72,985,406 | 990 |
Original Form 990 PDFs (the Form column) are served by ProPublica Nonprofit Explorer, as filed with the IRS. Create a free account to download the CSV report.
Leadership & compensation (FY2024)
Highest-paid: Dr Melvin Spigelman — $939,703 (1.53% of total expenses)
| Name | Title | Hours/week | Compensation |
|---|---|---|---|
| Dr Melvin Spigelman | President/ceo | 45 | $939,703 |
| Dr Eugene Sun | Sr. Vp, Research & Development | 45 | $580,925 |
| Dr Nader Fotouhi | Sr. Vp, Chief Scientific Officer | 45 | $565,207 |
| Maria Beumont | Vp, Chief Medical Officer | 45 | $497,709 |
| Colleen Pero | Secretary/cao | 45 | $470,044 |
| Robert Lorette | Sr. Vp, Business Development | 45 | $448,954 |
| Kathleen Schostack | Sr. Vp, Program & Alliance Management | 45 | $432,300 |
| Salah Foraida | Sr. Director, Medical Affairs | 45 | $430,090 |
| Angela Vanderploeg | Treasurer/cfo | 45 | $421,854 |
| Sandeep Juneja | Sr. Vp, Market Access | 45 | $417,509 |
| Rajneesh Taneja | Vp, Pharmaceutical Product Development | 45 | $370,728 |
| Pietro O Turilli | Sr. Vp, External Affairs | 45 | $369,474 |
| Akshay Vaishnaw | Director (as of 12/01/24) | 3 | — |
| Ann Taylor | Director (as of 09/01/24) | 3 | — |
| Ariel Pablos-mendez | Vice-chair | 3 | — |
| David Norton | Chair | 3 | — |
| Eric Goosby | Director | 3 | — |
| Kim Schwartz | Director | 3 | — |
| Mitchell Warren | Director | 3 | — |
| Rasha Hibri | Director | 3 | — |
Top vendors & contractors (FY2024)
| Contractor | Services | Paid |
|---|---|---|
| Ppd Development LP | Global Cro | $4,305,665 |
| Wuxi Apptec (hongkong) Limited | Integrated R&d Services | $3,501,842 |
| Cerba Research Nv | Lab Costs | $2,778,060 |
| Clininvent Research Pvt Ltd | Drug Manufacturing / Testing | $1,999,500 |
| Glaxosmithkline Investigacion | External Mini Portfolios | $1,600,000 |
Grants received · $3.0M total
7 grants to Global Alliance For Tb Drug Development Inc totaling $3.0M, reported by foundations on their Schedule I filings.
| Grantmaker | Purpose | Year | Amount |
|---|---|---|---|
| Vanguard Charitable Endowment Program | For recipient's exempt purpose | 2023 | $8,000 |
| National Philanthropic Tr | International | 2020 | $19,232 |
| National Philanthropic Tr | Public, societal benefit | 2017 | $1,500,000 |
| Johns Hopkins University | Sub-award | 2017 | $8,120 |
| Network For Good Inc | Unrestricted | 2016 | $7,411 |
| National Philanthropic Tr | Human services | 2015 | $316,770 |
| National Philanthropic Tr | International/fo | 2014 | $1,183,230 |
Grants made · $15K in FY2023
1 grant totaling $15K in FY2023. All grants made by Global Alliance For Tb Drug Development Inc →
| Recipient | Purpose | Amount |
|---|---|---|
| National Tuberculosis Coalition of America Inc | Comm. engage | $15,000 |
Similar organizations in Medical Research
Medical Research
Cardiovascular Research Foundation
New York, NY
$68.9M
Aannual revenue
- Medical Research
Licr Fund Inc
New York, NY
$79.0M
Aannual revenue
Medical Research
Parkinsons Foundation Inc
New York, NY
$84.2M
Aannual revenue
- Medical Research
International Brain Research Organization
New York, NY
$37.2M
C+annual revenue
Medical Research
The International Academy of Hope
New York, NY
$32.6M
Bannual revenue
Medical Research
The Foundation For Aids Research
New York, NY
$24.8M
C+annual revenue
Medical Research
Cancer Research Institute Inc
New York, NY
$24.0M
Dannual revenue
Medical Research
New York Stem Cell Foundation Inc
New York, NY
$23.1M
Dannual revenue
Medical Research
Childrens Tumor Foundation
New York, NY
$19.7M
Bannual revenue
- Medical Research
Winifred Masterson Burke Medical Research
White Plains, NY
$19.7M
Dannual revenue
Compare Global Alliance For Tb Drug Development Inc
Frequently asked questions
- Is Global Alliance For Tb Drug Development Inc a legitimate nonprofit?
- Yes. Global Alliance For Tb Drug Development Inc is a 501(c)(3) organization registered with the U.S. Internal Revenue Service under EIN 13-4128413, based in New York, New York. Donations are tax-deductible.
- What is Global Alliance For Tb Drug Development Inc's EIN?
- Global Alliance For Tb Drug Development Inc's Employer Identification Number (EIN) is 13-4128413.
- How much revenue does Global Alliance For Tb Drug Development Inc report?
- Global Alliance For Tb Drug Development Inc reported $63,732,557 in total revenue on its fiscal year 2024 IRS Form 990 filing.
- How much of Global Alliance For Tb Drug Development Inc's spending goes to programs?
- Global Alliance For Tb Drug Development Inc spends about 88% of its total expenses on programs, based on its latest IRS Form 990.
- What financial grade does Global Alliance For Tb Drug Development Inc have?
- CharityIndex grades Global Alliance For Tb Drug Development Inc A, based on program efficiency and fundraising cost.
- How much does Global Alliance For Tb Drug Development Inc's highest-paid employee make?
- The highest reported compensation on Global Alliance For Tb Drug Development Inc's latest Form 990 is $939,703, paid to Dr Melvin Spigelman (President/ceo).
More nonprofits in New York
Explore more
Data for Global Alliance For Tb Drug Development Inc (EIN 13-4128413) comes from the IRS Business Master File and e-filed Form 990 returns, via CharityIndex. Figures reflect what the organization reported to the IRS for each fiscal year.